Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Nephros Inc. (NEPH : NSDQ)

• Company Description    Nephros develops advanced End Stage Renal Disease, or ESRD, therapy technology and products that would address both patient treatment needs and the clinical and financial needs of the treatment provider. Number of Employees: 31

• Price / Volume Information    Yesterday's Closing Price: $5.23 Daily Weekly Monthly 20 Day Moving Average: 80,026 shares Shares Outstanding: 10.60 (millions) Market Capitalization: $55.44 (millions) Beta: 1.32 52 Week High: $5.98 52 Week Low: $1.38 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 25.12% 21.67% 12 Week 47.32% 37.51% Year To Date 255.78% 205.20%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 380 LACKAWANNA PLACE - SOUTH ORANGE,NJ 07079 USA ph: 201-343-5202 fax: 201-343-5207 ksmith@pcgadvisory.com http://www.nephros.com

• General Corporate Information    Officers Robert Banks - Chief Executive Officer and President Judy Krandel - Chief Financial Officer Arthur H. Amron - Director Oliver Spandow - Director Alisa Lask - Director Peer Information Nephros Inc. (BJCT) Nephros Inc. (CADMQ) Nephros Inc. (APNO) Nephros Inc. (UPDC) Nephros Inc. (IMTIQ) Nephros Inc. (CYGN) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED PRODUCTS Sector: Medical CUSIP: 640671400 SIC: 3841 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/06/25 Share - Related Items Shares Outstanding: 10.60 Most Recent Split Date: 7.00 (0.11:1) Beta: 1.32 Market Capitalization: $55.44 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: 0.00 Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/06/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: 43.58 PEG Ratio: - Price Ratios Price/Book: 5.78 Price/Cash Flow: 261.36 Price / Sales: 3.32 EPS Growth vs. Year Ago Period: 166.67% vs. Previous Quarter: -60.00% Sales Growth vs. Year Ago Period: 35.89% vs. Previous Quarter: -9.39% ROE 09/30/25 - - 06/30/25 - 14.89 03/31/25 - 9.43 ROA 09/30/25 - - 06/30/25 - 11.64 03/31/25 - 7.20 Current Ratio 09/30/25 - - 06/30/25 - 5.41 03/31/25 - 5.92 Quick Ratio 09/30/25 - - 06/30/25 - 4.14 03/31/25 - 4.64 Operating Margin 09/30/25 - - 06/30/25 - 7.95 03/31/25 - 5.16 Net Margin 09/30/25 - - 06/30/25 - 7.95 03/31/25 - 5.16 Pre-Tax Margin 09/30/25 - - 06/30/25 - 8.10 03/31/25 - 5.26 Book Value 09/30/25 - - 06/30/25 - 0.91 03/31/25 - 0.88 Inventory Turnover 09/30/25 - - 06/30/25 - 2.47 03/31/25 - 2.23 Debt-to-Equity 09/30/25 - - 06/30/25 - 0.00 03/31/25 - 0.00 Debt-to-Capital 09/30/25 - - 06/30/25 - 0.00 03/31/25 - 0.00

Powered by Zacks Investment Research ©